Zonisamide and psychosis

Journal of Epilepsy

Volumn 10, Issue 2, 1997, Pages 52-54

  Matsuura, M ^a   Trimble, M R ^b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PHENYTOIN; ZONISAMIDE;

CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; MENTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; TEMPORAL LOBE EPILEPSY;

EID: 0031552128     PISSN: 08966974     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6974(96)00083-7     Document Type: Article

References (18)

1. 1. Masuda Y, Karasawa T, Shiraishi Y, et al: 3-Sulfamoyl-methyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforschung 1980; 30:477-83.
2. 2. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7.
3. 3. Seino M, Naruto S, Ito T, et al. Zonisamide. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995:1011-23.
4. 4. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies - our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:79-85.
5. 5. Ono T, Yagi K, Seino M, et al. Clinical efficacy and safety of new antiepileptics: zonisamide (in Japanese). Seishin-Igaku 1988;30:471-82.
6. 6. Mayahara K, Kanemoto K, Kawasaki J, et al. Zonisamide and epileptic psychosis. (in Japanese with English abstract). J Jpn Epil Soc 1995;13:177-83.
7. 7. Kawasaki J, Sengoku A, Kanemoto K, et al. The occurrence of acute paranoid-hallucinatory state in epilepsy - in association with antiepileptic drugs (in Japanese). Seishin-Igaku 1991;33:595-600.
8. 8. Matsuura M, Senzaki A, Okubo Y, et al. Eight epileptic patients showing delusional-hallucinatory state during zonisamide administration (in Japanese). Seishin-Igaku 1993;35: 413-9.
9. 9. Hara S, Imasaka Y, Takei S, et al. Five cases of zonisamide-related psychosis: with particular reference to the drug interaction between zonisamide and phenytoin and to the risk factors for epileptic psychosis (in Japanese). Jpn J Psychiatric Ther 1993;8:59-64.
10. 10. Trimble MR. Anticonvulsant-induced psychiatric disorders. Drug Safety 1996;15:1-8.
11. 11. Landolt H. Serial electroencephalographic investigation during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorenz de Haes, ed. Lectures on epilepsy. Amsterdam; Elsevier, 1958;91-133.
12. 12. Teilenbach H. Epilepsie als Anfallsleiden und als Psychose. Uber alternative Psychosen paranoider Pragung bei "forcierter Normalisierung" (Landolt) des Elektroenzephalogramms Epileptischer. Nervenarzt 1965;36:190-202.
13. 13. Trimble MR. The psychosis of epilepsy. New York: Raven Press, 1991.
14. 14. Roger J, Grangeon H, Guey J, et al. Incidences psychiatriques et psychologiques du traitment par l'éthosuccimide chez les épileptiques. Encephale 1968;57:407-38.
15. 15. Wolf P. Acute behavioral symptomatology at disappearance of epileptiform EEG abnormality: paradoxical or "forced" normalization. In: Smith D, Treiman D, Trimble MR, eds. Neurobehavioral problems in epilepsy, New York: Raven Press, 1991;127-42. (Advances in neurology; vol 55.).
16. 16. Hori M, Ito T, Oka M, et al. General pharmacology of the novel anti-epileptic compound zonisamide. First communication: effects on central nervous system. Arzneimittelforschung 1987;37:1124-30.
17. 17. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release. Epilepsy Res 1992;12: 113-9.
18. 18. Wolf P, Trimble MR: Biological antagonism and epileptic psychosis. Br J Psychiatry 1985;146:272-6.